This Thursday evening, Trinity’s Neal Dunn will be participating on a panel for Life Science Cares to discuss industry career opportunities with students from the Bottom Line program. The event will be held at EY’s Boston offices from 5:30 – 8:00pm. Learn more about Life Science Cares events here: http://bit.ly/2iz0Pzj
MIT Technology Review Associate Editor Emily Mullin spoke with Trinity Partners’ Herman Sanchez about gene therapy pricing, specifically around the correlation between price of drug, and patient population size. Learn more from their conversation here: http://bit.ly/2xlZZfg
Trinity Partners, a leading global life sciences consulting firm, today announced that Dave Fitzhenry, Managing Partner, was named one of Consulting magazine’s Global Leaders in Consulting 2017. The Global Leaders in Consulting award recipients are chosen based upon their impact, initiative and extraordinary influence in their firms, for their clients and over the entire consulting profession.
“We are so proud of Dave for achieving this award. He was one of the firm’s first members and has proven his value and expertise many times over since day one,” said John Corcoran, Founder and President, Trinity Partners. “His insights consistently make a meaningful impact on critical business decisions for his clients and within our firm and his outstanding leadership has been instrumental in our unmatched global client and employee growth.”
Fitzhenry, a graduate of Harvard University, joined Trinity Partners as the firm’s third employee in 1997 and currently serves as its managing partner. He is a sought-after expert in commercial strategy in the biopharmaceutical industry and his experience includes work with global organizations, as well as in-depth knowledge of the critical areas for new product development. Fitzhenry has extensive knowledge in global markets, across a variety of therapeutic areas and with companies of all sizes, ranging from biotech startups to large-cap pharmaceuticals.
Fitzhenry will be recognized at a celebratory gala awards dinner at Le Meridian Piccadilly in London, United Kingdom on Thursday, December 7 and also included in the January 2018 issue of Consulting magazine.
Trinity Partners, a leading global life sciences consulting firm, today announced, at the NORD Rare Disease and Orphan Products Breakthrough Summit in Washington, D.C., a new whitepaper titled ‘Assessing Value in Ultra-Orphan Markets’.
In the last five to 10 years, the concentration on orphan development has exploded. From acquisitions to creation of separate rare disease units, pharma companies of all sizes have an increased focus on the orphan market. Yet, while rare diseases have the attention of the industry and the incentives continue to be strong, finding success in the orphan market is not easy. This new whitepaper outlines the crucial clinical and commercial attributes that drive success for ultra-orphan, non-oncology products.
Key insights include:
- Potential products (to acquire or for portfolio planning) must first be assessed on several different commercial and clinical criteria specific to ultra-orphan markets.
- Success in the ultra-orphan market does not follow one formula. Soliris (Alexion) and KUVAN (BioMarin) are two assets that score high with regard to clinical and commercial opportunity, yet followed very different paths to success.
- The complexities surrounding success in the ultra-orphan market will continue to grow as competition rises alongside increased payer and pricing sensitivity.
“There are more than 7,000 rare diseases with only 500 approved treatments, which is a clear indicator of a large unmet need and opportunity for success in the orphan market space,” said Herman Sanchez, Partner, Trinity Partners, and lead author of the report. “However, being aware that there is a large market opportunity and truly realizing that opportunity are very different things. Our whitepaper outlines key insights and findings based on our deep commercialization experience in the market, providing companies with a proven roadmap to recognize the critical metrics that determine success and the efforts needed to achieve them.”
Trinity Partners, headquartered in Waltham, MA, with additional offices in San Francisco, New York City and Princeton, New Jersey, has extensive experience in orphan and ultra-orphan markets globally including NA, EUMEA, LATAM and APAC. The firm has more than 150 employees and has worked with six of the top 12 global pharmaceutical companies and 12 of the top 20 specialty and biopharmaceutical companies.
“The industry is driving to more targeted therapies, including new and exciting gene therapies, and many of them could become success stories with the right considerations. We’ve worked with many companies in the U.S. and around the globe on their commercialization strategies and are excited to share key learnings in our new whitepaper,” added Neal Dunn, Partner, Trinity Partners and co-author of the whitepaper.
NORD’s Rare Diseases and Orphan Products Breakthrough Summit is the largest and most meaningful multi-stakeholder event of its kind – featuring more than 20 speakers from the FDA, participation from over 80 patient organizations and the Pharma/Biotech industry’s foremost experts in orphan product innovation, investment and commercialization.
To read the full whitepaper and access all key insights, click here.
On September 6th, several Trinity employees attended the Life Science Cares Mini Golf for Good Tournament & Food Truck Showdown in Cambridge. The team had a great time honing their putt-putt skills and checking out the local food trucks. Life Science Cares is a collective effort of the life sciences industry to eliminate the impact of poverty in the greater Boston area. Trinity is honored to work with this great organization to support the development of grant programs and funding partnerships to fight poverty in our local communities.
Trinity team members to bring expertise to international oncology and strategic conferences
Trinity Partners, a leading global life sciences consulting firm, today announced it will attend several leading industry conferences being held in the U.S. and Europe this Fall. Covering topics from oncology research and product launches to customer data management, Trinity executives are looking forward to learning more about oncology research, product launches, data governance and value-based oncology management to continue to address the complex business questions that confront pharmaceutical, biotech, and medical device companies worldwide.
Trinity executives will attend several key events, including:
- September 8-12: Partner Herman Sanchez and Principal Alex Chiang attended the ESMO2017 Congress in Madrid, Spain to learn about how science is being integrated into oncology to improve patient outcomes.
- September 11-12: Senior Consultant Vivian DeWoskin attended the CBI Product Launch Summit in Boston, Massachusetts to hear about the latest trends in pre-launch planning, payer negotiation and product uptake.
- October 17-18: Associate Director John Gillis will attend the CBI Commercial Data Insights Conference in Philadelphia, Pennsylvania to learn about the integration, validation and governance of master data to advance customer intelligence.
- October 24-25: Partner John Greenaway will attend CBI Value Based Oncology Care Conference in Scottsdale, Arizona to hear about the latest trends in value-based oncology management.
“Trinity’s philosophy is to help clients develop innovative analyses that produce robust evidence and strategic insight,” said Herman Sanchez, Partner, Trinity Partners. “We look forward to leveraging key takeaways to help our clients make informed decisions in today’s rapidly-changing life sciences landscape.”
Jillian Godfrey Scaife, Principal, will also participate in a Healthcare Businesswomen’s Association panel on currents events in biotechnology on October 18. During the discussion, held at Amgen’s new facility in Cambridge, Massachusetts, Jillian will speak about the latest news and developments in drug pricing and biosimilars.
About Trinity Partners
Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here.
Check out the full article and insights from John in PharmaVOICE’s September issue, online here: http://bit.ly/2wI7w8H
Trinity Partners, a global life sciences consulting firm, today announced that it has welcomed its 21st annual class of recent graduates, onboarding 25 new hires. Hailing from top universities across the nation including Harvard, Duke, Vanderbilt, Dartmouth and Williams, these new additions to the company will join practice areas including Strategy Consulting, Advanced Analytics and Primary Market Research.
Trinity provides new hires with a comprehensive onboarding program to ensure they are set up for success, including hands-on sessions facilitated by over 60 percent of our tenured staff; a full client engagement simulation; and discussions focused on acclimating to the industry and general corporate work environment.
“Fostering employee growth and career development is one of Trinity’s top priorities,” said Michelle Adams, HR Director at Trinity Partners. “We are thrilled to welcome this class of new graduates in to a fast-paced work environment where they can learn as they grow, be exposed to new opportunities, and help biopharmaceutical companies tackle their most pressing business challenges.”
Trinity has more than 150 employees with offices in San Francisco, Princeton, New Jersey and New York City. Coming out of a busy first half of 2017, headlined by the release of a whitepaper analyzing the correlation between drug price and value, Trinity is well-positioned to continue to help clients identify opportunities and pain points. The company maintains an unwavering commitment to the development of its employees that drive its continued growth and broadening influence in the life sciences industry.
“No matter the industry or role, it is imperative to get some perspective. We are looking forward to seeing how Trinity’s new team members will be able to approach our unique business from an alternative angle, delivering meaningful and measurable results,” said Dave Fitzhenry, Partner at Trinity Partners.
About Trinity Partners: Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here.
Trinity employees ran and power-walked to support the battle against cancer at the RACE Cancer Foundation 5K on August 10th in Boston. RACE programs create opportunities to reduce and detect cancer through education, prevention, and screening measures. 100 percent of funds raised at RACE running events benefit organizations such as the Leukemia & Lymphoma Society, Target Cancer Foundation and the Multiple Myeloma Research Foundation. Trinity had a great time meeting other members of the Greater Boston community who are dedicated to helping in the fight against cancer.
Last week, Trinity employees spent an afternoon organizing, menu planning, cooking and serving lunch to individuals at the Community Day Center of Waltham. The Day Center, a not-for-profit organization, provides a warm, welcoming place and services for people who are homeless and those who may feel alone and isolated. Trinity encourages all employees to dedicate a portion of their time to volunteer work in the local community.